Table 1 (abstract A50). See text for description
From: Abstracts of the ICARE 2024 78th SIAARTI National Congress
Patients’ Characteristics | |
|---|---|
Age (years), median (IQR) | 52 (46–59) |
Gender (female) N (%) | 4 (16.7) |
BMI, median (IQR) | 28.34 (25–36.7) |
PBW (kg), median (IQR) | 67.7 (63.7–70.5) |
SAPS II, median (IQR) | 22 (18.5–27) |
APACHE II, median (IQR) | 54.5 (45–64) |
SOFA score on ICU admission, median (IQR) | 9.5 (6–12) |
NIV before OTI, N (%) | 12 (50) |
Days on MV before vvECMO, median (IQR) | 7.5 (2.5–11) |
 Non-COVID-19 | 6 (2–8) |
 COVID-19 | 11 (7–13) |
Days on NIV plus MV before vvECMO, median (IQR) | 10 (3.5–16) |
 Non-COVID-19 | 8 (3–13) |
 COVID-19 | 18 (11–22) * |
PaO2/FiO2 before vvECMO, median (IQR) | 74.9 (61.35–78.5) |
PaO2/FiO2 during vvECMO, median (IQR) | 180 (137.4–228.7) |
COVID-19, N (%) | 7 (29,2) |
Pplat before vvECMO, median (IQR) | 28 (26–29) |
 Non-COVID-19 | 28 (27–29) |
 COVID-19 | 26 (24–29) |
Pplat during vvECMO, median (IQR) | 25.7 (24.3–27.1) |
 Non-COVID-19 | 26 (25.1–27.3) |
 COVID-19 | 24.6 (23.7–25.7) |
Cstat before vvECMO, median (IQR) | 30 (25.5–39) |
 Non-COVID-19 | 31 (30–40) |
 COVID-19 | 28 (21.4–37.5) |
Days on vvECMO, median (IQR) | 14.5 (10–21.5) |
 Non-COVID-19 | 13 (10–21) |
 COVID-19 | 15 (10–22) |
MDR infections, N(%) | 18 (75) |
 Klebsiella pneumoniae | 11 (45.8) |
 Pseudomonas aeruginosa | 3 (12.5) |
 Acinetobacter | 4 (16.7) |
 E. Coli | 1 (4.17) |
 MRSE | 5 (20.8) |
Microbial culture, N(%) | |
 BAL | 17 (70.8) |
 Bloodstream | 10 (41.67) |